Antibiotic Resistance Scout
Discovery Lens
C Combination Innovation
Two separate worlds finally connect — and the intersection is a product
One-Liner
An AI platform for infectious disease clinicians that takes a bacterial resistance profile as input and outputs computationally predicted drug repurposing candidates, synergistic combinations, and phage therapy matches.
Kill Reason
Clinical decision support software for prescribing decisions requires FDA SaMD clearance and EU MDR certification — a multi-year regulatory pathway that would consume all early capital before a single hospital can legally act on the output. The phage therapy matching component relies on a therapeutic category with no approved products in the US or EU, making that differentiator commercially premature by at least five years.
What do you think?
Related ideas you can explore free:
killed: Passive voice-based depression detection requires FDA Software as a Medical Device clearance for any diagnostic claim; a "wellness" framing undercuts the core value proposition and reduces willingness to pay. Epic Systems and large telehealth platforms are already integrating validated mental health screening tools into clinical workflows, crowding out standalone apps before they achieve scale.
killed: Google Nest Hub's built-in Soli radar-based sleep sensing already delivers contactless respiratory monitoring in millions of households, and Withings has shipped FDA-cleared sleep apnea screening hardware. A standalone $30 WiFi module cannot match the distribution, brand trust, or regulatory standing of these well-resourced incumbents.
killed: Urine and stool analysis for glucose monitoring, cancer screening, and kidney function markers falls squarely into FDA Class II/III medical device territory, requiring clinical trials and 510(k) or PMA approval costing millions and taking years. The entire high-value use case — the reason anyone would buy this — is legally undeliverable without regulatory clearance the product cannot realistically obtain.